Patents Assigned to Istituto Superiore di Sanita
-
Publication number: 20240148745Abstract: The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. The compounds have been identified through methods of pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.Type: ApplicationFiled: March 9, 2022Publication date: May 9, 2024Applicants: FONDAZIONE CENTRO SAN RAFFAELE, INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, SORBONNE UNIVERSITE, WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, HEINRICH HEINE UNIVERSITY DÜSSELDORF, UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY, ISTITUTO SUPERIORE DI SANITÀ, CONSIGLIO NAZIONALE DELLE RICERCHE, IRBM S.P.A.Inventors: Gianvito MARTINO, Paola PANINA, Brahim NAIT-OUMESMAR, Anne BARON-VAN EVERCOOREN, Tanja KUHLMANN, Sergio BARANZINI, Norbert GOEBELS, Frauke ZIPP, Nicholas HANUSCHECK, Jack ANTEL, Cristina AGRESTI, Maria Pia ABBRACCHIO, Ivano EBERINI, Chiara PARRAVICINI, Stefania OLLA, Alberto BRESCIANI
-
Publication number: 20230364211Abstract: The present invention concerns a nucleotide sequence expressing a fusion protein, said fusion protein comprising or consisting of an exosome-anchoring protein fused at its C-terminus with an antigen, or a DNA expression vector comprising said nucleotide sequence, for use as vaccine.Type: ApplicationFiled: January 20, 2023Publication date: November 16, 2023Applicant: ISTITUTO SUPERIORE DI SANITÀInventor: Maurizio Paolo Maria FEDERICO
-
Patent number: 11065221Abstract: There is disclosed buthionine sulfoximine (BSO) for use in a method of treatment of cancer, HIV or a rheumatic disease. The method comprises administering (a) BSO at a dosage of less than or equal to 50 mg/kg, and (b) a metallodrug at a clinically-acceptable dosage.Type: GrantFiled: March 23, 2018Date of Patent: July 20, 2021Assignee: ISTITUTO SUPERIORE DI SANITÀInventors: Iart Luca Shytaj, Shailendra Pratap Singh Rathore, Francesco Procopio, Andrea Savarino
-
Publication number: 20210113669Abstract: The present application relates to the use of bacterial CNF (Cytotoxic Necrotizing Factor) and/or DNT (dermonecrotic toxin) as active ingredients or active ingredient for the prevention and/or the treatment of malaria caused by Plasmodium falciparum, pharmaceutical compositions comprising said active ingredient(s) for said use and a method of prevention and/or treatment of malaria, comprising the administration of bacterial CNF (Cytotoxic Necrotizing Factor) and/or DNT (dermonecrotic toxin) or of a composition comprising it/them to a patient in need thereof.Type: ApplicationFiled: July 27, 2017Publication date: April 22, 2021Applicant: ISTITUTO SUPERIORE DI SANITAInventors: Carla FIORENTINI, Francesco SILVESTRINI, Stefano LOIZZO, Valeria MESSINA, Sara TRAVAGLIONE, Pietro ALANO
-
Publication number: 20200181704Abstract: A method can determine Attention-Deficit Hyperactivity Disorder (ADHD) and/or evaluate the prognosis and/or determine the effectiveness of a therapy against ADHD. The method is based on measuring the methylation levels of CpG dinucleotides and/or CpG islands in a genomic region of the SLC6A3 gene (solute carrier family 6 member 3), preferably in the 5? UTR.Type: ApplicationFiled: December 21, 2017Publication date: June 11, 2020Applicants: Istituto Superiore di Sanita', Universita' degli Studi di Teramo, Universita' degli Studi di Roma "La Sapienza"Inventors: Giovanni LAVIOLA, Walter ADRIANI, Esterina PASCALE, Claudio D'ADDARIO
-
Publication number: 20200022937Abstract: There is disclosed buthionine sulfoximine (BSO) for use in a method of treatment of cancer, HIV or a rheumatic disease. The method comprises administering (a) BSO at a dosage of less than or equal to 50 mg/kg, and (b) a metallodrug at a clinically-acceptable dosage.Type: ApplicationFiled: March 23, 2018Publication date: January 23, 2020Applicant: ISTITUTO SUPERIORE DI SANITÀInventors: Iart Luca Shytaj, Shailendra Pratap Singh Rathore, Francesco Procopio, Andrea Savarino
-
Patent number: 10507207Abstract: The invention refers to the use of Reverse Transcriptase (RT) inhibitor compounds for the preparation of pharmaceutical compositions to counteract the loss of cellular differentiation in tumour and non tumour pathologies, said compound being able to bind the hydrophobic pocket on the RT subunit p66. Particularly preferred for such uses are the following compounds: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivatives thereof.Type: GrantFiled: December 23, 2002Date of Patent: December 17, 2019Assignee: ISTITUTO SUPERIORE DI SANITAInventors: Corrado Spadafora, Patriźia Ĺavia, Elisabetta Mattei, Gugliemo Palombini, Rodolfo Nello Lorenzini, Clara Nervi
-
Patent number: 9969780Abstract: Complexes comprising HIV Tat and the V3 loop from gp120 Env provide novel epitopes and are immunogenic to prevent or inhibit infection by HIV.Type: GrantFiled: March 11, 2005Date of Patent: May 15, 2018Assignee: Istituto Superiore di SanitaInventor: Barbara Ensoli
-
Patent number: 9732359Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.Type: GrantFiled: December 8, 2015Date of Patent: August 15, 2017Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Istituto Superiore di SanitaInventors: Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
-
Patent number: 9610334Abstract: The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.Type: GrantFiled: March 19, 2014Date of Patent: April 4, 2017Assignees: Istituto Superiore di Sanita, NovaDigm Therapeutics, Inc.Inventors: Rinaldo Zurbriggen, Flavia De Bernardis, Antonio Cassone, Silvia Rasi
-
Patent number: 9428557Abstract: Tat protein produced in bulk culture is inactive when induced at conventional optical densities but can be obtained in biologically active form when induced during the logarithmic growth phase.Type: GrantFiled: February 6, 2009Date of Patent: August 30, 2016Assignees: ISTITUTO SUPERIORE DI SANITA, UNIVERSITA DEGLI STUDI DI URBINOInventors: Barbara Ensoli, Mauro Magnani
-
Publication number: 20160201062Abstract: Provided is the use of antisense RNA and methods for the treatment, diagnosis and prophylaxis of cancer comprising administering said antisense RNA, particularly miRs 15 and 16 to a patient in need thereof.Type: ApplicationFiled: January 5, 2016Publication date: July 14, 2016Applicant: Istituto Superiore di SanitaInventors: Desiree Bonci, Ruggero De Maria
-
Patent number: 9261508Abstract: Provided is the use of antisense RNA and methods for the treatment, diagnosis and prophylaxis of cancer comprising administering said antisense RNA, particularly miRs 15 and 16 to a patient in need thereof.Type: GrantFiled: April 27, 2009Date of Patent: February 16, 2016Assignee: Istituto Superiore Di SanitaInventors: Desiree Bonci, Ruggero De Maria
-
Patent number: 9216214Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.Type: GrantFiled: December 16, 2014Date of Patent: December 22, 2015Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Istituto Superiore di SanitaInventors: Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
-
Patent number: 8926987Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.Type: GrantFiled: November 17, 2005Date of Patent: January 6, 2015Assignees: The Government of The United States of America as represented by the Secretary of the Department of Health and Human Services, Istituto Superiore di SanitaInventors: Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
-
Patent number: 8834873Abstract: Methods are provided for treating cancer metastasis by administering a therapeutic composition targeting a kinase substrate cascade.Type: GrantFiled: October 31, 2007Date of Patent: September 16, 2014Assignees: George Mason Research Foundation, Inc., Istituto Superiore di SanitaInventors: Emanuel F. Petricoin, III, Mariaelena Pierobon, Valerie Calvert, Lance A. Liotta
-
Publication number: 20140227238Abstract: The present invention concerns peptides having protective effect towards inflammatory activity of a-gliadin 31-43 peptide in celiac disease and therefore can be used for preventive and therapeutic purpose by administration thereof to subjects at high risk to develop celiac disease and/or celiac subjects just before a gluten containing meal to be ingested.Type: ApplicationFiled: September 18, 2012Publication date: August 14, 2014Applicants: Istituto Superiore Di Sanita, CRA-Sonsiglio per La Ricerca E LAInventors: Marco Silano, Luigi Cattivelli, Pasquale De Vita, Luigi Maiuri, Donatella Bianca Maria Ficco
-
Patent number: 8785493Abstract: Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.Type: GrantFiled: October 29, 2009Date of Patent: July 22, 2014Assignee: Istituto Superiore di SanitaInventors: Andrea Savarino, Antonello Mai, Anna Teresa Palamara, Enrico Garaci
-
Publication number: 20140193445Abstract: The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.Type: ApplicationFiled: March 19, 2014Publication date: July 10, 2014Applicants: Istituto Superiore Di Sanita, Pevion Biotech Ltd.Inventors: Rinaldo Zurbriggen, Flavia De Bernardis, Antonio Cassone, Silvia Rasi
-
Patent number: 8715698Abstract: The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.Type: GrantFiled: September 19, 2008Date of Patent: May 6, 2014Assignees: Pevion Biotech, AG, Istituto Superiore di SanitaInventors: Rinaldo Zurbriggen, Flavia de Bernardis, Antonio Cassone, Silvia Rasi